<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145517</url>
  </required_header>
  <id_info>
    <org_study_id>FLOWGRAFT</org_study_id>
    <nct_id>NCT05145517</nct_id>
  </id_info>
  <brief_title>A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts</brief_title>
  <acronym>FLOWGRAFT</acronym>
  <official_title>FLOWGRAFT - A Post-Market Clinical Follow-up Study in Patients Treated With Vascular Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JOTEC GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JOTEC GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FLOWGRAFT post-market clinical follow-up study is undertaken to show the safety and&#xD;
      performance of FlowWeave Bioseal, FlowNit Bioseal, FlowLine Bipore and FlowLine Bipore&#xD;
      Heparin (combined named as Vascular Grafts) in the treatment of arterial diseases, such as&#xD;
      dissection, aneurysm, intramural hematoma (IMH), penetrating aortic ulcer (PAU), contained&#xD;
      rupture, stenosis in the aorta or peripheral arteries (lower limbs). This includes the use of&#xD;
      FlowWeave Bioseal or FlowNit Bioseal for debranching of the head vessels in an alone standing&#xD;
      procedure. Furthermore, it includes the use of the FlowLine Bipore and FlowLine Bipore&#xD;
      Heparin Grafts as arterious-venous (AV) shunt.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients who receive a Vascular Graft for the treatment of arterial diseases&#xD;
      (aneurysm, PAU, IMH, dissection, stenosis) of the aorta or peripheral arteries (lower limbs)&#xD;
      or as an AV shunt will be observed. This includes patients in whom the Vascular Grafts are&#xD;
      used for debranching or reconstruction of the head vessels. Participating physicians will be&#xD;
      asked to provide the observations, that were collected during routine care. Written informed&#xD;
      consent, specifically allowing the use of clinical records for this observational study, will&#xD;
      be obtained from every patient prior to data collection.&#xD;
&#xD;
      The period of data collection will be approximately 60 + 6 months (depending on the date of&#xD;
      the last follow-up visit) from the date of intervention for each patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30-day</time_frame>
    <description>Rate of in-hospital all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30-day, 6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Graft-related adverse event</measure>
    <time_frame>30-day, 6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with Vascular Graft-related adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Vascular Graft -related hemorrhage</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with freedom from Vascular Graft -related hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Graft stenosis &gt; 50% or occlusion</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with Vascular Graft stenosis &gt; 50% or occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Graft primary patency</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with Vascular Graft primary patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Graft secondary patency (after reintervention)</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with Vascular Graft secondary patency (after reintervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudoaneurysm at the sutures or in the Vascular Graft</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with pseudoaneurysm at the sutures or in the Vascular Graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Graft infection</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with vascular Graft infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New sepsis</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with new sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New stroke</measure>
    <time_frame>6-month,12-month, 24-month, 36-month, 60-month</time_frame>
    <description>Rate of patients with new stroke</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Vascular Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Open repair</intervention_name>
    <description>Open repair of the aorta and peripheral arteries</description>
    <other_name>Open repair of the aorta and peripheral arteries</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with arterial disease who are scheduled to be treated with a&#xD;
        Vascular Graft according to the instructions for use and their physician's discretion in&#xD;
        accordance with the inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 years at time of written informed consent&#xD;
&#xD;
          -  Patient was selected for treatment with a commercially available Vascular Graft of&#xD;
             JOTEC&#xD;
&#xD;
          -  Patient satisfies at least one of the following categories:&#xD;
&#xD;
               -  Acute (14 days) / subacute (15 - 90 days) dissection with double lumina in the&#xD;
                  aorta or peripheral artery / arteries (lower limb)&#xD;
&#xD;
               -  Chronic (&gt;90 days) dissection with double lumina in the aorta or peripheral&#xD;
                  artery / arteries (lower limb)&#xD;
&#xD;
               -  Aneurysm in the aorta or peripheral artery / arteries (lower limb)&#xD;
&#xD;
               -  IMH in the aorta or peripheral artery / arteries (lower limb)&#xD;
&#xD;
               -  PAU in the aorta or peripheral artery / arteries (lower limb)&#xD;
&#xD;
               -  Contained rupture in the aorta or peripheral artery / arteries (lower limb)&#xD;
&#xD;
               -  Stenosis in the aorta or peripheral artery / arteries (lower limb)&#xD;
&#xD;
               -  Debranching of head vessels&#xD;
&#xD;
               -  AV shunt&#xD;
&#xD;
          -  Patient is willing and able to comply with all clinical study procedures and study&#xD;
             visits.&#xD;
&#xD;
          -  Patient has given written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has any other medical, social, or psychological problem that in the opinion of&#xD;
             the investigator preclude them from receiving this treatment, procedures, and&#xD;
             evaluations pre- and post-procedure.&#xD;
&#xD;
          -  Patient is scheduled for reconstruction of the tibial artery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Oberhuber, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Münster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heike Fischer, Dr.</last_name>
    <phone>+4915115397110</phone>
    <email>fischer.heike@cryolife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Oberhuber, Prof. Dr.</last_name>
    <phone>+49 251 83-45782</phone>
    <email>alexander.oberhuber@ukmuenster.de</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic</keyword>
  <keyword>aneurysm</keyword>
  <keyword>dissection</keyword>
  <keyword>stenosis</keyword>
  <keyword>PAU</keyword>
  <keyword>IMH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

